State Street SPDR S&P Biotech ETF (XBI)
An exchange-traded fund listed on AMEX. A fund is not a company: it has no filed accounts of its own here, and it is never ranked beside companies. Every figure below is market data, with the day it was supplied.
Price
Last close 149.78 USD on Oct 15, 2026. Market data, supplied Oct 15, 2026.
What it costs
| Expense ratio | 0.35% |
| Assets under management | 10.05B USD |
| Net asset value per share | 146.73 USD |
| Inception | Jan 31, 2006 |
| Sponsor | SPDR |
| Asset class | Equity |
| Holdings the fund reports | 165 |
Market data, supplied Oct 15, 2026.
What it holds
The largest 25 by weight of the 167 holdings in the snapshot of Oct 15, 2026. A fund is marked as a fund, and a holding that is not a company's share (a bond, a bill, cash, an option or a swap) is marked as not a company.
| # | Holding | Weight |
|---|---|---|
| 1 | MODERNA INC | 2.58% |
| 2 | NATERA INC | 1.84% |
| 3 | TWIST BIOSCIENCE CORP | 1.82% |
| 4 | ABBVIE INC | 1.73% |
| 5 | BIOGEN INC | 1.71% |
| 6 | AMGEN INC | 1.68% |
| 7 | HALOZYME THERAPEUTICS INC | 1.68% |
| 8 | IOVANCE BIOTHERAPEUTICS INC | 1.67% |
| 9 | UNITED THERAPEUTICS CORP | 1.64% |
| 10 | GILEAD SCIENCES INC | 1.63% |
| 11 | EXELIXIS INC | 1.61% |
| 12 | TG THERAPEUTICS INC | 1.54% |
| 13 | REGENERON PHARMACEUTICALS | 1.49% |
| 14 | VERTEX PHARMACEUTICALS INC | 1.48% |
| 15 | KRYSTAL BIOTECH INC | 1.47% |
| 16 | PROTAGONIST THERAPEUTICS INC | 1.44% |
| 17 | REVOLUTION MEDICINES INC | 1.44% |
| 18 | GRAIL INC | 1.43% |
| 19 | CRISPR THERAPEUTICS AG | 1.42% |
| 20 | VAXCYTE INC | 1.40% |
| 21 | SPYRE THERAPEUTICS INC | 1.40% |
| 22 | INCYTE CORP | 1.37% |
| 23 | PTC THERAPEUTICS INC | 1.36% |
| 24 | NEUROCRINE BIOSCIENCES INC | 1.35% |
| 25 | ALNYLAM PHARMACEUTICALS INC | 1.34% |
Market data, supplied Oct 15, 2026.
Sector weights
| Healthcare | 99.28% |
| Financial Services | 0.72% |
Market data, supplied Oct 15, 2026.
Country weights
| United States | 95.31% |
| Switzerland | 1.42% |
| Ireland | 1.41% |
| United Kingdom | 1.24% |
| Netherlands | 0.44% |
| Other | 0.17% |
Market data, supplied Oct 15, 2026.
Look-through value
Earnings yield, P/E and book yield of the holdings taken together: n/a. Look-through figures are not measured for this fund yet.